Brian M. Shuch, MD Yale School of Medicine, discusses how S1500’s Completion May Alter Standard of Care for PRCC Compares…
Walter M. Stadler, MD University of Chicago, discusses how they May Select Patients for VEGF or PD-1 Targeted Further investigation…
Maxine Sun, MD Dana-Farber Cancer Institute, discusses The Importance of Statistical Analysis Plans Minimize errors, reduce amount of surprises, &…
Robert Uzzo, MD Fox Chase Cancer Center, discusses the Role of Government in Health Care Political climate raises questions on…
Walter M. Stadler, MD University of Chicago, discusses Biomarker Data From Phase II Trial Preliminary expression profiling at Kidney Cancer…
Brian M. Shuch, MD Yale School of Medicine, discusses the SWOG S1500 – Randomized Phase II Trial Efficacy assessment of…
Tian Zhang, MD Duke University Medical Center, explains the Challenges of VEGF & Immunotherapy Combinations Resistance patterns in patients disease…
Robert Uzzo, MD Fox Chase Center, explains how Value is a Function of Outcomes and Cost Optimal care is not…
Walter M. Stadler, MD University of Chicago, discusses Biomarker Data From Phase II Randomized Trial Study of Atezolizumab With or…
Brian M. Shuch, MD Yale School of Medicine, discusses the Difference Between Type 1 & 2 PRCC Although look similar…
Maxine Sun, MD Dana-Farber Cancer Institute, discusses The Use of Secondary Data Analysis Opportunity to produce high-impact research at Kidney…
Michael B. Atkins, MD Deputy Director Professor, Oncology & Medicine Georgetown Lombardi Comprehensive Cancer Center answers if there is Any…
Andrew Chi, MD, PhD at NYU Langone Medical Center Explains how Gliomas in Mid-Line Locations are Distinct in Both Genetic…
Michael B. Atkins, MD Deputy Director Professor, Oncology & Medicine Georgetown Lombardi Comprehensive Cancer Center answers how Data will not…
Michael B. Atkins, MD Deputy Director Professor, Oncology & Medicine Georgetown Lombardi Comprehensive Cancer Center answers What happens to patients…
Michael B. Atkins, MD Deputy Director Professor, Oncology & Medicine Georgetown Lombardi Comprehensive Cancer Center answers if doseage of axitnib…
Michael B. Atkins, MD Deputy Director Professor, Oncology & Medicine Georgetown Lombardi Comprehensive Cancer Center answers How do you indentify…
Pharmacists play a valuable role in oncology practice. Here, R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, from the Winship Cancer…
R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, from the Winship Cancer Institute, Atlanta, GA, gives a pharmacists perspective on the…
R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, from the Winship Cancer Institute, Atlanta, GA, discusses the importance of biomarkers in…
Here, the 2017/18 President of the Hematology/Oncology Pharmacy Association (HOPA), Susannah Koontz Webb, PharmD, BCOP, FHOPA, provides an insight into…
Year after year, the number of healthcare professionals that join the Hematology/Oncology Pharmacy Association (HOPA) continues to increase. Speaking from…
What can be expected from the Hematology/Oncology Pharmacy Association (HOPA) in 2018/19? Here, Susannah Koontz Webb, PharmD, BCOP, FHOPA, 2017/18…
It was a very productive year for the 2017/18 governance of the Hematology/Oncology Pharmacy Association (HOPA). Here, Susannah Koontz Webb,…
This year the Hematology/Oncology Pharmacy Association (HOPA) held its 14th Annual Conference in Denver, CO, with a record-breaking number of…
Cutaneous graft-versus-host disease (GVHD) can be a long-term complication of stem cell transplantation that requires careful management. Speaking from the…
The European Cancer Patient Coalition (ECPC) is a large European cancer patients organization, comprising hundreds of patient groups from many…
Specialist organizations, such as the European Group for Blood and Marrow Transplantation (EBMT), can provide a range of useful tools…
The European Group for Blood and Marrow Transplantation Nurses Group (EBMT NG) is committed to improving medical education worldwide, to…
The European Group for Blood and Marrow Transplantation Nurses Group (EBMT NG) is a rich resource for nurses and allied…
The European Group for Blood and Marrow Transplantation (EBMT) held its 44th Annual Meeting in 2018, with delegates once again…
Veno-occlusive disease (VOD) is a serious complication that can occur following stem cell transplantation, for which the appropriate management is…
The European Group for Blood and Marrow Transplantation Nurses Group (EBMT NG), founded in 1985, is a well-established coalition that…
The European Group for Blood and Marrow Transplantation (EBMT) is committed to developing and advancing the care of patients. In…
Michael B. Atkins, MD Deputy Director Professor, Oncology & Medicine Georgetown Lombardi Comprehensive Cancer Center discusses the efficacy of axitinib…
In this video, Dr. Brian G.M. Durie explains that second transplant and certain novel therapies may work well for early…
In this weeks video, Brian G.M. Durie explains that even though Revlimid and Pomalyst may reduce white blood cell counts,…
In this weeks video, Dr. Brian G.M. Durie explains that supplements might have side effects or might interfere with medications…
Dr. Karen Reckamp, MD, MS, Co-Director of the Lung Cancer and Thoracic Oncology Program, Medical Director – Clinical Research Operations,…
Dr. Karen Reckamp, MD, MS, Co-Director of the Lung Cancer and Thoracic Oncology Program, Medical Director – Clinical Research Operations,…
Dr. Luis Raez, MD FACP FCCP, Chief of Hematology/Oncology and Medical Director at Memorial Cancer Institute, and Clinical Associate Professor…
Dr. Luis Raez, MD FACP FCCP, Chief of Hematology/Oncology and Medical Director at Memorial Cancer Institute, and Clinical Associate Professor…
We are pleased to have Nathan Pennell, MD, PhD, Director of Lung Cancer Medical Oncology at the Cleveland Clinic Taussig…
We are pleased to have Nathan Pennell, MD, PhD, Director of Lung Cancer Medical Oncology at the Cleveland Clinic Taussig…
We are pleased to have Nathan Pennell, MD, PhD, Director of Lung Cancer Medical Oncology at the Cleveland Clinic Taussig…
Dr. Nate Pennell, Director of Lung Cancer Medical Oncology at Cleveland Clinic Taussig Cancer Center shares 2017 updates for our…
http://cancerGRACE.org/
http://cancerGRACE.org/
http://cancerGRACE.org/
http://cancerGRACE.org/
Dr. Jack West offers discussions for 2017 regarding the changing standard of care for stage 3 non-small cell lung cancer…
Lung Cancer Video Library http://cancerGRACE.org/
Lung Cancer Video Library http://cancerGRACE.org/
Lung Cancer Video Library http://cancerGRACE.org/
Lung Cancer Video Library http://cancerGRACE.org/
Dr. West discusses exciting new advances in NSCLC – PDL1 as a Biomarker for First Line.
Lung Cancer Video Library http://cancerGRACE.org/
Lung Cancer Video Library http://cancerGRACE.org/
Lung Cancer Video Library http://cancerGRACE.org/
Lung Cancer Video Library http://cancerGRACE.org/
Lung Cancer Video Library http://cancerGRACE.org/
Lung Cancer Video Library. http://cancerGRACE.org/
Lung Cancer Video Library http://cancerGRACE.org/
Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, discusses the demographics and epidemiology of lung cancer.
Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, discusses the demographics and epidemiology of lung cancer.
Presented by Dr. Luis E. Raez, MD, FACP, FCCP Chief of Hematology/Oncology and Medical Director of Memorial Cancer Institute (Miami,…
Presented by Dr. Luis E. Raez, MD, FACP, FCCP Chief of Hematology/Oncology and Medical Director of Memorial Cancer Institute (Miami,…
Presented by Dr. Luis E. Raez, MD, FACP, FCCP Chief of Hematology/Oncology and Medical Director of Memorial Cancer Institute (Miami,…
Presented by Dr. Luis E. Raez, MD, FACP, FCCP Chief of Hematology/Oncology and Medical Director of Memorial Cancer Institute (Miami,…
Presented by Dr. Luis E. Raez, MD, FACP, FCCP Chief of Hematology/Oncology and Medical Director of Memorial Cancer Institute (Miami,…
Presented by Dr. Luis E. Raez, MD, FACP, FCCP Chief of Hematology/Oncology and Medical Director of Memorial Cancer Institute (Miami,…
Presented by Dr. Luis E. Raez, MD, FACP, FCCP Chief of Hematology/Oncology and Medical Director of Memorial Cancer Institute (Miami,…
Andrew Chi, MD, PhD at NYU Langone Medical Center Explains How they Will Work with Distant Patients to Get Them…
Andrew Chi, MD, PhD at NYU Langone Medical Center Explains How NYU is 1st Actively Enrolling Site for ONC201 in…
Andrew Chi, MD, PhD at NYU Langone Medical Center Explains How Patients Must Have H3 K27M Tumor Mutation for Clinical…
Andrew Chi, MD, PhD at NYU Langone Medical Center Explains How ONC201 is Taken Orally with Minimal Side Effects. Clinical…
Andrew Chi, MD, PhD at NYU Langone Medical Center Explains How Patients Must Have Progressive Disease after 1st Line of…
Andrew Chi, MD, PhD at NYU Langone Medical Center Explains Phase 2 Clinical Trial of ONC201 in Patients with Glioma…
Andrew Chi, MD, PhD at NYU Langone Medical Center explains how K27M Mutations are Rare within Gliomas, an Already Rare…
Andrew Chi, MD, PhD at NYU Langone Medical Center explains how ONC201 has Selectivity Anti-Cancer Properties and is a Dopamine…
Presented by Aziz Nazha, MD. Acute myeloid leukemia (AML) is generally a hematologic malignancy of older adults, with approximately 60%…
Presented by Ehab Atallah, MD. There is a significant unmet need in existing treatment paradigms for patients with acute myeloid…
Immunotherapy has the potential to provide long-term benefits to certain lung cancer patients; however, certain patients may not respond, while…
Informal carers play an essential role in the care of many lung cancer patients. Here, Morag Farquhar, PhD, of the…
Breathlessness is a frightening and disabling symptom of lung cancer; therefore, it is vital that patients, carers, family and healthcare…
Breathlessness is a scary symptom for lung cancer patients and their family, who often act as informal carers. Speaking from…
Patient advocacy, by individuals and organizations, serves an imperative role in healthcare, giving a voice to those who are most…
The neuroendocrine tumor (NET) Patient Foundation is a valuable resource for patients with NETs, as well as their carers. Here,…
CAR T-cells are an exciting therapeutic area, which although promising are still in the early stages of development for solid…
There are numerous ongoing and planned clinical trials investigating immuno-oncology (IO) agents for lung cancer, particularly in combination with other…
For lung cancer, early diagnosis and staging is crucial to survival. However, the length of the lung cancer pathway differs…
Exciting clinical trial updates were presented at the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland.…
In the coming era of lung cancer management, where the use of both targeted agents and new immunotherapies seems extremely…
A key subject on everyones mind at the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland,…
The British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland, hosted sessions covering a diverse range of…
This is an exciting time for research into the early diagnosis of lung cancer, with a number of promising options…
There is a growing need to improve the early diagnosis of lung cancer; non-invasive, quick and accessible assays would greatly…
A non-invasive biomarker assay to detect lung cancer would be ideal; avoiding needless biopsies and providing another step of diagnostic…
One issue with lung cancer screening is that nodules, which may or may not be malignant, can be detected, leading…
With rapid advancements in the management of lung cancer, new questions and challenges undoubtedly arise. Here, James Spicer, PhD, FRCP,…
As explained here by James Spicer, PhD, FRCP, of Guy’s and St Thomas’ NHS Foundation Trust, London, UK, the field…
As our understanding of the different oncogenes that serve a role in the pathogenesis of lung cancer increases, so does…
Lung cancer screening is an exciting and greatly debated topic in the UK; on one hand it could greatly improve…
Lung cancer management in the UK is on the pinnacle of great change, with the current implementation of the National…
The National Optimal Lung Cancer Pathway (NOLCP), a hugely accelerated new lung cancer care pathway in the UK, was a…
Tobacco use is a major determinant of lung cancer risk; therefore, it is vital that a patients smoking status and…
The National Optimal Lung Cancer Pathway (NOLCP), a streamlined care pathway to improve the speed of lung cancer diagnosis, staging…
The past several years have been extremely exciting in the field of bladder cancer, with checkpoint inhibitors emerging as efficacious…
The 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, hosted an exciting Best of Journals session, highlighting key research…
Despite there now being a variety of promising immunotherapies for bladder cancer, a large proportion of patients dont respond to…
Ashkan Lashkari, MD, shares Dr. Kesari on Neuro-Oncology Some patients do well if given treatments in neoadjuvantat the 2018 Oncology…
Ashkan Lashkari, MD, shares Dr. Fakih’s Talk on Colorectal Cancer Microsatellite instability is an approved biomarker at the 2018 Oncology…
Ashkan Lashkari, MD, shares Dr. Hurvitzs Study on Breast Cancer Using Tumor-Infiltrating Lymphocytes as a biomarker at the 2018 Oncology…
Ashkan Lashkari, MD, shares Dr. Reckcamp Overview on Lung Cancer Combine established Immunotherapy with new therapies at the 2018 Oncology…
Ashkan Lashkari, MD, shares Dr. Hamid On Metastatic Melanoma IDO Inhibitors can help overcome resistance at the 2018 Oncology Summit…
Ashkan Lashkari, MD, shares Dr. Powells Study On RCC & Bladder Tumors Augment treatment responses with good safety signals at…
Ashkan Lashkari, MD, gives a MOASC Overview – Highlights from Presentations A number of speakers talk across different tumor types…
Santosh Kesari, MD, explains Looking Forward to Mature Data on Glioblastoma Updates from Antibody-based trials at the 2018 Oncology Summit…
Santosh Kesari, MD, explains Patients May Benefit from Molecular Profiling of Tumor BRAF, PI3K, etc, would benefit from available drugs…
Santosh Kesari, MD, discusses how Immunotherapy Can have Activity in the Brain Do better at managing toxicities at the 2018…
Santosh Kesari, MD, Immunotherapy in Glioma Study in the neoadjuvant setting at the 2018 Oncology Summit in Huntington Beach, CA…
There was exciting news in the field of bladder cancer treatment at the 2018 Genitourinary Cancers Symposium, held in San…
Whether or not patients with prostate cancer with adverse pathological features (APF) following radical prostatectomy should be offered radiotherapy immediately…
Patients with oligometastatic prostate cancer can be identified using highly advanced detection tools, such as positron emission tomography (PET) and…
Bladder preservation remains a viable option for certain patients with bladder cancer; with previous studies showing that patients up to…
The ProtecT trial (NCT02044172) was a study conducted between 1999 and 2009 that compared active monitoring, radical prostatectomy and radiotherapy…
An interesting update on the ProtecT trial (NCT02044172) was given by Freddie Hamdy, MBChB, LRCSPEd, LRCSEd, LRCPSGlasg, FRCSEd, MD, FRCSEd(Urol),…
Patient reported outcomes (PROs) are reports that can provide insightful information from patients, including how they feel about their condition…
Active monitoring, radical prostatectomy or radiotherapy? For men with clinically localized prostate cancer, which intervention has a disease-specific mortality advantage?…
The nurses role in talking about trials was an interesting session run by the UK Oncology Nursing Society (UKONS) symposium…
The National Cancer Research Institute (NCRI) invited the UK Oncology Nursing Society (UKONS) to host a session at the 2017…
Discussing clinical trials with young cancer patients can be tricky; are there certain strategies that can be implemented to help…
It has been found that the Clinical Nurse Specialist has a central role working alongside research nurses and doctors to…
There was exciting news at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, with…
To date, stem cell transplantation has been the best curative treatment method for acute leukemia, for which T-cells are the…
Acute leukemias can exhibit resistance to T-cell engaging antibodies through immune evasion, via both innate and adaptive mechanisms. In this…
T-cell engaging antibodies are more straightforward to deisgn and use in acute lymphoblastic leukemia (ALL) compared with acute myeloid leukemia…
Dr. Thomas George, Medical Director of GI Oncology Program at the University of Florida and a NSABP Principal Investigator discusses…
What were the objectives of the Hokusai venous thromboembolism (VTE)-Cancer Study? In this interview, Harry Buller, MD, PhD, of the…
Venous thromboembolism (VTE) remains a major risk for patients with cancer. The current standard of care for VTE includes subcutaneously…
Our knowledge of early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) is advancing, as highlighted by an excellent talk on the…
Dr. Karen Reckamp, MD, MS, Co-Director of the Lung Cancer and Thoracic Oncology Program, Medical Director – Clinical Research Operations,…
We are continually learning new facts about the molecular basis of acute lymphoblastic leukemia (ALL) and how it is evolving.…
CAR T-cells for acute lymphoblastic leukemia (ALL) treatment are promising, with a number of different agents in development. Here, Bijal…
It is now widely agreed that minimal residual disease (MRD) is a clinically relevant measure, so how can we now…
Certain molecular lesions are inherently targetable in acute lymphoblastic leukemia (ALL); patients with these changes should be given access to…
Now that our techniques to measure minimal residual disease (MRD) are highlighly sensitive, the utility of MRD to guide and…
Marwan Fakih, MD, explains Identify Who Can Take Immunotherapy in the First-Line The durability of responses would be much better…
Marwan Fakih, MD, shares Presented Data has Affected Day-to-Day Practice Has already been affecting MSI-High patients at the 2018 Oncology…
Sara A Hurvitz, MD, FACP Associate Professor of Medicine Director, Breast Oncology, shares Comparative Studies in the Neoadjuvant setting All…
Marwan Fakih, MD, explains Disappointing Data for Patients without MSI Great responses to checkpoint inhibitors at the 2018 Oncology Summit…
Sara A Hurvitz, MD, FACP Associate Professor of Medicine Director, Breast Oncology, examines Trials Evaluating Immunotherapies for Breast Cancer Either…
Marwan Fakih, MD, explains Lack of Randomized Data to Compare Drugs Nivolumab + Ipilimumab showed high response rate Randomized Data…
ara A Hurvitz, MD, FACP Associate Professor of Medicine Director, Breast Oncology, explains Not Using Anthracycline-based Therapies Patients accumulate loss…
Marwan Fakih, MD, explains Microsatellite Instability in Colorectal Cancer PD-1 Inhibitors have a significant response rate at the 2018 Oncology…
Sara A Hurvitz, MD, FACP Associate Professor of Medicine Director, Breast Oncology, examines Immune Therapy Toxicities Related to Breast Cancer…
Omid Hamid MD Chief, Translational Research/Immuno-Oncology Director shares, TAPUR Study – FDA approved therapies Targeted therapies such as BRAF, CDK2NA,…
Sara A Hurvitz, MD, FACP Associate Professor of Medicine Director, Breast Oncology, shares Immunotherapy Not Recommended Outside Trials Pembrolizumab for…
Omid Hamid MD Chief, Translational Research/Immuno-Oncology Director explains, Metastases Treated with Anti-CTLA-4 & Anti-PD-1 Shows immunotherapies to affect brain metastases…
Sara A Hurvitz, MD, FACP Associate Professor of Medicine Director, Breast Oncology, examines Studies in Neoadjuvant, Curative, & Metastatic Settings…
Omid Hamid MD Chief, Translational Research/Immuno-Oncology Director explains, Creating Roadmap for Therapies for Solid Tumors Encouraging data shows multiple options…
Sara A Hurvitz, MD, FACP Associate Professor of Medicine Director, Breast Oncology, examines Immune-Targeted Therapy in Breast Cancer Immune System…
Omid Hamid MD Chief, Translational Research/Immuno-Oncology Director explains, 238 Trial – Nivolumab as Standard for Melanoma Therapeutics Available for Relapsed…
Acute myeloid leukemia (AML) is experiencing a therapy boom, with increasing numbers of novel treatments being approved and more in…
Elderly patients with secondary acute myeloid leukemia (AML) typically had poor outcomes following standard chemotherapy treatment. However, this changed in…
CPX-351, a combination of cytarabine (ara-C) and daunorubicin within a liposomal delivery system, was approved in August 2017 for two…
The liposomal delivery of chemotherapy is a promising therapeutic area, which was highlighted by the approval of CPX-351 for two…
Hear about exciting advancements in acute lymphocytic leukemia (ALL) with Prof. David Marks, MBBS, PhD, FRACP, FRCPath, of University Hospitals…
In this exciting interview, Irene Higginson, OBE, BMBS, PhD, FMedSci, FRCP, of Kings College London, London, UK, introduces the palliative…
Nelarabine has shown to be effective in treating relapsed/refractory T-cell acute lymphocytic leukemia (T-ALL) in children and adults; however, there…
Can patients with B-cell acute lymphocytic leukemia (ALL) benefit more from using rituximab as part of their treatment compared to…
In recent years, there has been a lot of debate surrounding how palliative care should be integrated into the cancer…
Palliative care can offer patients with progressive cancer a better quality of life, but how can this type of care…
Karen Reckamp, MD, MS Medical Director, Clinical Research Operations shares When Will Tumor Mutational Burden be a Standard Trials analyzing…
Karen Reckamp, MD, MS Medical Director, Clinical Research Operations shares Stage III Lung Cancer Receptible vs. Unreceptible at the 2018…
Karen Reckamp, MD, MS Medical Director, Clinical Research Operations explains Refine Patient Subsets & Define Combinations at the 2018 Oncology…
Karen Reckamp, MD, MS Medical Director, Clinical Research Operations explains New Lung Cancer Data Already in the Forefront Upcoming meetings…
Karen Reckamp, MD, MS Medical Director, Clinical Research Operations shares First-Line Therapy for Squamous Cell Lung Cancer Multiple Positive Trials…
Karen Reckamp, MD, MS Medical Director, Clinical Research Operations shares the Continuation to Refine Understanding of Biomarkers and Find the…
Omid Hamid MD Chief, Translational Research/Immuno-Oncology Director presents, Immunotherapy in Melanoma at the 2018 Oncology Summit in Huntington Beach, CA…
In this weeks video, Dr. Brian G.M. Durie advises that patients discuss with their doctors the many aspects of various…
In this weeks video, Dr. Brian G.M. Durie emphasizes the importance of correctly diagnosing and staging myeloma before beginning treatment…
Robert Uzzo, MD Fox Chase Cancer Center, discusses Several Elements Factor into Rising Drug Costs Time, development, and innovation adds…
In this weeks video, Dr. Brian G.M. Durie explains that the underlying biology of light chain myeloma is very similar…
In this weeks video, Dr. Brian G.M. Durie compares two trials that treat high-risk smoldering multiple myeloma the CESAR trial…
In this weeks video, Dr. Brian G.M. Durie explains the somewhat confusing results of the IFM 2009 trial. BOTTOM LINE:…
In this weeks video, Dr. Brian G.M. Durie defines minimal residual disease (MRD) and explains how MRD-testing can be used…
In this weeks video, Dr. Brian G.M. Durie explains why myeloma patients should discuss the use of supplements with their…
In this weeks video, Dr. Brian G.M. Durie addresses why the cost of patented drugs, such as Revlimid, have not…
Santosh Kesari, MD, PhD, Chair, Department of Neurosciences and Neurotherapeutics, John Wayne Cancer Institute & Pacific Neuroscience Institute examines Immunotherapy…
Sara A Hurvitz, MD, FACP Associate Professor of Medicine Director, Breast Oncology, examines The Role of Immunotherapy in Breast Cancer…
Marwan Fakih, MD, explains Investigating the Tumor Immune Response to Optimize Treatment in Colorectal Cancer at the 2018 Oncology Summit…
Karen Reckamp, MD, MS Medical Director, Clinical Research Operations provides an in-depth look at Harnessing the Power of ImmunotherapyLung Cancer…
Karen Reckamp, MD, MS Medical Director, Clinical Research Operations shares Lung Cancer Immunotherapy Advances PDL-1 and Tumor Mutational Burden at…
Sumanta (Monty) Kumar Pal, M.D. Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research Co-director, Kidney Cancer Program, Medical…
Sumanta (Monty) Kumar Pal, M.D. Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research Co-director, Kidney Cancer Program, Medical…
Sumanta (Monty) Kumar Pal, M.D. Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research Co-director, Kidney Cancer Program, Medical…
Sumanta (Monty) Kumar Pal, M.D. Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research Co-director, Kidney Cancer Program, Medical…
Sumanta (Monty) Kumar Pal, M.D. Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research Co-director, Kidney Cancer Program, Medical…
Sumanta (Monty) Kumar Pal, M.D. Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research Co-director, Kidney Cancer Program, Medical…
Sumanta (Monty) Kumar Pal, M.D. Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research Co-director, Kidney Cancer Program, Medical…
Immune checkpoint inhibitors are a promising area of therapy, with our understanding of their mechanism of action and the ways…
As our knowledge of immunotherapy increases, so has our understanding of its side effects. In this interview, Naval Daver, MD,…
The use of immune checkpoint inhibitor therapy for acute myeloid leukemia (AML) has progressed drastically over the past several years.…
Aberrations in sonic hedgehog (shh) signaling are known to be associated with certain types of cancer, including acute myeloid leukemia…
Low-dose cytarabine (ara-C) is not generally perceived as a good therapy for AML, particularly in the US, whereas hypomethylating agents…
Therapeutically targeting the sonic hedgehog (shh) signaling pathway for the treatment of acute myeloid leukemia (AML) is an exciting area,…
MOASC Oncology Summit Kick Off March 3rd, 2018. Dr. Warren H. Fong, MD MOASC President kicks off the 2018 Oncology…
A plethora of novel treatments for acute myeloid leukemia (AML) are emerging, providing an increasing choice of therapies and bringing…
A stimulating session on the implications of genomic data for the management of acute myeloid leukemia (AML) and acute lymphoblastic…
An interesting session on the impact of genomic data on the management of acute myeloid leukemia (AML) and acute lymphoblastic…
Interesting results were produced in the PROUD-PV Study (NCT01949805), which compared the treatment of ropeginterferon alpha-2b with hydroxyurea in patients…
An exciting update on the 4-year follow-up of the RESPONSE Trial (NCT01243944) was given by Jean-Jacques Kiladjian, MD, PhD, of…
Treating patients who suffer from myelofibrosis with interferon used to be considered inappropriate due to the drug being poorly tolerated.…
Recent insights from the genomic analysis of acute lymphoblastic leukemia (ALL) were presented at the 1st International Workshop on Acute…
The genomic analysis of acute lymphoblastic leukemia (ALL) is providing novel insights into the disease, which will inform and direct…
With the excitement surrounding novel therapeutics, reliable conventional treatments can often be overlooked. The optimization of standard treatments is a…
Acute myeloid leukemia (AML) is typically a disease affecting older people, and there are increasing numbers of elderly AML patients…
The 1st International Workshop on Acute Leukemias (iwAL), held in St. Pete Beach, FL, was a great success, with the…
CAR T-cells are a very promising therapeutic for hematological malignancies, with more in development for B-cell compared with T-cell malignancies.…
Immunotherapy is an exciting area, with advocates, sceptics and those who remain undecided without further research. The 1st International Workshop…
Our understanding of acute myeloid leukemia (AML) has made great strides in recent years, informing the direction of therapeutic strategies.…
The 1st International Workshop on Acute Leukemias (iwAL), held in St. Pete Beach, FL, hosted though-provoking discussion on the topic…
The 1st International Workshop on Acute Leukemias (iwAL), held in St. Pete Beach, FL, hosted an exciting session on treatment…
The use of minimal residual disease (MRD) in the management of acute leukemias is a hotly debated topic. Despite the…
Minimal residual disease (MRD) has become a major tool in the monitoring of hematological malignancies; however, its utility can be…
Minimal residual disease (MRD) is a hot topic in the world of oncology and many talks on the topic were…
Could the progression of smoldering multiple myeloma (SMM) be better predicted? In this interview, Irene Ghobrial, MD, from the Dana-Farber…
The primary focus is often on treatment within the United States or Europe, but what about treatment on a global…
As high-risk patients with multiple myeloma (MM) continue to die from the disease, novel treatments are needed. In this interview,…
Although genetics and epigenetics serve an important role in the efficacy of novel agents such as ibrutinib, other factors must…
With new developments in the treatment of patients with chronic lymphocytic leukemia (CLL), is there a possibility of eradicating the…
As lung cancer screening is a relatively new area, particularly to non-healthcare professionals, understanding of the procedure and risks involved…
Tian Zhang, MD Duke University Medical Center, VEGF is Immunomodulatory & Decreases Regulatory T-Cell Responses Significant progress in the field…
Aly-Khan Lalani, MD Dana Farber Cancer Institute, discusses Geographic Outcomes of Metastatic RCC in Canada & Europe ESMO-MCBS shows real…
André P Fay, MD Hospital Mãe De Deus Cancer Institute, discusses Impact of Geographic Region in Clinical Outcome of Metastatic…
Tian Zhang, MD Duke University Medical Center, discusses Many VEGF Phase 3 Trials Have Completed Accrual Colleagues can visit clinicaltrials.gov…
Robert Uzzo, MD Fox Chase Cancer Center, discusses Physician-Directed Patient-Oriented Improvements How physicians can deliver the best care & cost-intensive…
Aly-Khan Lalani, MD Dana Farber Cancer Institute, discusses Canada Negotiates Drug Prices w Pan-Canadian Consortium Sunitinib & Pazopanib are most…
Tian Zhang, MD Duke University Medical Center, discusses Early Phase VEGF Trials Enhance Responses in the 1st Line Could lead…
Robert Uzzo, MD Fox Chase Cancer Center, discusses Economic Research and Value in Kidney Cancer Value incentivizes provider & delivery…
Aly-Khan Lalani, MD Dana Farber Cancer Institute, discusses Sunitinib V. Pazopanib in the First Line Setting Patients receiving sunitinib had…
Dr. Jack West explores the importance of following the overall survival of patients on the PACIFIC trial and considers still…
Following cancer treatment, it is important to support and enable an increasing number of cancer survivors to live as healthy…
Following the promising results of initial investigations into the use of an electronic healthcare assessment tool in the delivery of…
Integrating technology into healthcare service delivery can improve patient experience whilst improving efficiency. In this interview, Pamela Rose, Macmillan Lung…
Disease monitoring is important to determine what is happening with patients outside of the clinical setting. Speaking from the American…
Exciting advancements in acute myeloid leukemia (AML) research were discussed during the American Society of Hematology (ASH) 2017 Annual Meeting…
Despite the remarkable progress being made in the treatment of patients with acute promyelocytic leukemia (APL), a high rate of…
CAR T-cells are a universally exciting area in hematological oncology. Speaking from the American Society of Hematology (ASH) 2017 Annual…